Mal-PEG2-VCP-NB - CAS 2395887-69-9 Catalog number: BADC-01106

Mal-PEG2-VCP-NB is a specialized bioconjugate that combines the maleimide (Mal) group, a polyethylene glycol (PEG2) spacer, a VCP (Valine-Citrulline-PAB) linker, and nitrobenzyl (NB) groups. This compound is primarily used in targeted drug delivery and cancer therapy. The maleimide group reacts efficiently with thiol groups on biomolecules like antibodies or peptides, enabling stable conjugation. The PEG2 spacer improves solubility, reduces immunogenicity, and enhances the pharmacokinetics of the conjugate, ensuring it remains in circulation longer. The VCP linker can be cleaved in the tumor microenvironment, facilitating controlled drug release. The NB group can undergo photochemical activation, allowing for targeted therapy activation via light exposure, making it a versatile tool in photodynamic therapy.

One of the primary applications of Mal-PEG2-VCP-NB is in the development of antibody-drug conjugates (ADCs) for cancer treatment. By attaching cytotoxic drugs or other therapeutic agents to antibodies through the VCP linker, the drug is delivered specifically to tumor cells expressing target antigens. The maleimide group enables efficient conjugation to the antibody’s thiol groups, while the PEG2 spacer enhances the solubility and circulation time, ensuring that the conjugate reaches the tumor site. The NB moiety adds an additional layer of precision by enabling light-induced activation of the drug in the tumor microenvironment, thereby improving the selectivity and effectiveness of treatment while minimizing damage to surrounding healthy tissue. This approach can be highly effective in cancers that are difficult to treat with conventional therapies.

Mal-PEG2-VCP-NB also shows promise in the development of photochemically activated therapies. The nitrobenzyl (NB) group within the conjugate can undergo photochemical activation when exposed to specific wavelengths of light. This property makes Mal-PEG2-VCP-NB ideal for use in photodynamic therapy (PDT) or photochemical internalization (PCI), where light is used to activate the drug selectively at the tumor site. This type of activation minimizes the risk of systemic toxicity, as the therapeutic agent remains inert until targeted by light. Photodynamic therapy is particularly beneficial in treating localized tumors and for therapies requiring minimal invasiveness, offering an innovative alternative to traditional methods like chemotherapy or radiation therapy.

Another important application of Mal-PEG2-VCP-NB is in the development of targeted diagnostic imaging agents. The conjugate can be used to label imaging probes, such as fluorescent dyes or radiolabeled compounds, which can be directed to specific cells or tissues of interest. The PEG2 spacer ensures the conjugate remains soluble and stable in vivo, while the VCP linker provides a mechanism for controlled release of the imaging agent. The NB group can be leveraged for specific activation in imaging techniques like fluorescence imaging or positron emission tomography (PET). This allows for precise tumor detection, localization, and monitoring of therapeutic efficacy in real time, aiding in personalized treatment planning and improving clinical outcomes.